Clonal aberrations of TP53 gene—either hemizygous deletion of the short arm of chromosome 17 (del17p) or mutations—adversely affect the prognosis of multiple myeloma (MM) patients, regardless of therapy [3–5]. This evidence concerns the gene TP53 and plasma cell myeloma.